Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/39025
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBiller, Beverly MK-
dc.contributor.authorGilis-Januszewska, Aleksandra-
dc.contributor.authorDoknic, Mirjana-
dc.contributor.authorPico, Antonio-
dc.contributor.authorFleseriu, Maria-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2026-01-27T11:01:19Z-
dc.date.available2026-01-27T11:01:19Z-
dc.date.created2025-
dc.identifier.citationThe Journal of Clinical Endocrinology & Metabolism 2025es_ES
dc.identifier.urihttps://hdl.handle.net/11000/39025-
dc.description.abstractAdult growth hormone (GH) deficiency (GHD) is characterized by metabolic abnormalities caused by insufficient GH production. Lonapegsomatropin, a prodrug administered once weekly, was designed to provide sustained release of unmodified somatropin to reduce the burden of daily somatropin injections.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent40es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGrowth hormonees_ES
dc.subjectGrowth hormone deficiencyes_ES
dc.subjectLong-acting growth hormonees_ES
dc.subjectAdult growth hormone deficiencyes_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes_ES
dc.titleEfficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Resultses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1210/clinem/dgaf680es_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 FORESIGTH.pdf

844,43 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???